RETATRUTIDE – User Manual & Dosage Protocol Guide

Retatrutide (LY‑3437943) is an investigational triple hormone receptor agonist that targets:

• GLP‑1 (glucagon‑like peptide‑1)
• GIP (glucose‑dependent insulinotropic polypeptide)
• Glucagon receptors

This unique mechanism aims to enhance appetite suppression, glycemic control, and energy expenditure — showing impressive results in early clinical trials for obesity and metabolic health. (pep-pedia.org)

Disclaimer: Retatrutide is for authorized research use only. It is not approved for human use outside regulated clinical trials, and attempting self‑administration carries serious safety and legal risks. (Drugs.com)

Retatrutide combines three hormone‑targeting effects:

• GLP‑1 receptor activation: suppresses appetite and slows gastric emptying
• GIP receptor activation: enhances insulin secretion and may improve fat metabolism
• Glucagon receptor activation: increases energy expenditure and fat oxidation

This triple agonism can promote greater weight loss and metabolic benefit compared with single or dual agonists. (pep-pedia.org)

Retatrutide is administered once weekly by subcutaneous injection in all clinical protocols. Dosage is typically titrated gradually to improve tolerance and reduce the incidence of gastrointestinal side effects. (Peptides.org)

IMPORTANT: There is no FDA‑approved dosing schedule as of now; all information below is based on published Phase 2 clinical trial data and investigational research. (Drugs.com)

Dosing Phases

Initial Phase (Weeks 1–4) – Example Weekly Dose: 1–2 mg | Notes: Assess tolerance and initial response

Titration Phase (Weeks 5–8) – Example Weekly Dose: 4 mg | Notes: Gradual escalation if tolerated

Mid Phase (Weeks 9–12) – Example Weekly Dose: 8 mg | Notes: Continued escalation

Advanced Phase (Week 13+) – Example Weekly Dose: 12 mg (max studied) | Notes: Target dose in most trials

Start low (e.g., 1–2 mg/week) and escalate every 4 weeks if tolerated. (Peptides.org)

The maximum weekly dose studied in trials is 12 mg/week. (Peptides.org)

In some research guides, initial conservative dosing may begin as low as 0.5–1 mg/week. (Peptide Protocols)

This pattern reflects clinical trial titration and not a recommended medical regimen. (Peptides.org)

Preparation

1. Ensure sterile technique: wash hands, disinfect vial tops.
2. Reconstitute lyophilized peptide with appropriate sterile bacteriostatic water, following research protocols.
3. Gently mix; do not shake vigorously.

Injection

1. Select a suitable site (abdomen, thigh, or upper arm).
2. Clean with alcohol swab.
3. Insert needle at approximately 45° angle for subcutaneous delivery.
4. Inject slowly and apply gentle pressure.

Timing:

• Once weekly on the same day each week for consistency. (pep-pedia.org)

Storage Information

Lyophilized Powder – Storage: Cool, dry place | Notes: Up to labeled expiration

Reconstituted Solution – Storage: Refrigerate (2–8 °C) | Notes: Use within recommended stability window

Discard if discolored, cloudy, or contaminated.

• Not approved for clinical use outside trials. (Drugs.com)
• Only administered under institutional review board (IRB) or clinical study oversight.
• Injection of unregulated peptides can lead to infection, dosing errors, metabolic disturbances, or serious adverse events.
• Avoid products labeled “research peptide” or purchased outside controlled research settings; many online vendors sell unregulated or counterfeit material. (bodyspec.com)
• Side effects observed in trials include GI symptoms, dose‑dependent nausea, and other metabolic effects.

Warning: Do not self‑administer or adjust doses without qualified clinical oversight.

Weekly Dose Schedule

Week 1–4 – Weekly Dose: 1–2 mg | Notes: Initial tolerance period

Week 5–8 – Weekly Dose: 4 mg | Notes: Escalation if tolerated

Week 9–12 – Weekly Dose: 8 mg | Notes: Mid‑range dose

Week 13+ – Weekly Dose: Up to 12 mg | Notes: Highest studied dose

Adjustments in trials are based on tolerance and side effect profile, not rigid schedules. (Peptides.org)

• Retatrutide has shown significant weight loss outcomes (e.g., ~24.2% average by 48 weeks at 12 mg in Phase 2). (Peptides.org)
• Trials also report metabolic improvements including glycemic control and liver fat reduction. (Peptides.org)
• Regulatory approval is pending; projected availability could be late 2026 or later depending on trial outcomes and regulatory review. (Drugs.com)

This manual is educational only. Retatrutide is still in clinical development. Any dosing regimen mentioned is investigational and has not been approved for clinical use. Never self‑administer investigational compounds, especially those obtained outside regulated research environments. Always consult licensed medical researchers or clinicians.